European Journal of Cancer Prevention最新文献_第8页

The global, regional, and national burden of colorectal cancer attributable to smoking from 1990 to 2021: a population-based study. 1990年至2021年吸烟导致的全球、区域和国家结直肠癌负担：一项基于人群的研究

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-22 DOI: 10.1097/CEJ.0000000000000957

Shuai Wang, Tao Zhang, Dongming Li, Xueyuan Cao

{"title":"The global, regional, and national burden of colorectal cancer attributable to smoking from 1990 to 2021: a population-based study.","authors":"Shuai Wang, Tao Zhang, Dongming Li, Xueyuan Cao","doi":"10.1097/CEJ.0000000000000957","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000957","url":null,"abstract":"Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide, with smoking being a significant risk factor. Understanding the temporal and spatial patterns of the CRC burden attributable to smoking is crucial for global public health strategies. Data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 were used to calculate the number of deaths, disability-adjusted life years (DALYs), age-standardized mortality rate (ASMR) per 100 000 population, and age-standardized disability-adjusted life year rate (ASDR). The average annual percentage change (AAPC) was calculated from 1990 to 2021 to analyze disease burden trends. Frontier analysis was conducted to assess efficiency, and predictions were made for the next decade. In 2021, the global death toll and DALYs attributable to smoking were 47 613 and 1 235 667, respectively. From 1990 to 2021, the absolute number of deaths and DALYs increased, while ASMR (AAPC: -1.20) and ASDR (AAPC: -1.22) showed a significant decline. The disease burden was notably higher in males than females. Analysis by the Social Development Index revealed that more developed regions had a higher burden than less developed areas. China ranked first in the number of deaths and DALYs, while Greenland had the highest ASMR and ASDR. From 1990 to 2021, the age-standardized burden of CRC attributable to smoking decreased globally. However, the absolute burden remains a significant public health challenge, requiring sustained and targeted interventions.","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a prediction model based on Hemoglobin, Albumin, Lymphocyte count, and Platelet-score for lymph node metastasis in rectal cancer. 建立基于血红蛋白、白蛋白、淋巴细胞计数和血小板评分的直肠癌淋巴结转移预测模型。

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-22 DOI: 10.1097/CEJ.0000000000000954

Huanhui Liu, Qian Zou, Hanjing Zhang, Xiaojie Ma

{"title":"Development of a prediction model based on Hemoglobin, Albumin, Lymphocyte count, and Platelet-score for lymph node metastasis in rectal cancer.","authors":"Huanhui Liu, Qian Zou, Hanjing Zhang, Xiaojie Ma","doi":"10.1097/CEJ.0000000000000954","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000954","url":null,"abstract":"This study aimed to evaluate the ability of the preoperative Hemoglobin, Albumin, Lymphocyte count, and Platelet (HALP) score to predict lymph node metastasis (LNM) in patients with rectal cancer (RC) and improve prediction accuracy by incorporating clinical parameters. Data from 263 patients with RC were analyzed. The receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value (OCV) for the HALP score in predicting LNM. Based on this cutoff value, patients were divided into two groups. A baseline analysis was conducted to identify independent factors linked to LNM. A support vector machine (SVM) prediction model was developed, and its performance was evaluated using ROC, calibration curves, decision curve analysis, and Kolmogorov-Smirnov curve. The OCV for HALP score was 45.979. Patients were then classified into a low HALP group (n = 182) and a high HALP group (n = 81). The analysis found 21 clinical factors significantly associated with LNM. Among them, the key risk factors included high inflammatory status, poor nutritional condition, and a low HALP score. The SVM model incorporated these factors and showed robust predictive performance, with area under the curve values of 0.897, 0.813, and 0.750 for the training, validation, and testing datasets, respectively. The HALP score was significantly associated with LNM in RC patients. A machine learning model integrating the HALP score and inflammatory markers may be an effective tool for predicting LNM in RC.","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation between skin cancer and therapy with anti-IL monoclonal antibodies in patients affected by moderate-to-severe psoriasis: an observational monocentric study. 中重度牛皮癣患者的皮肤癌与抗il单克隆抗体治疗的相关性：一项观察性单中心研究

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-07 DOI: 10.1097/CEJ.0000000000000948

Flavia Manzo Margiotta, Cristian Fidanzi, Simone Pardossi, Alessandra Michelucci, Giammarco Granieri, Giorgia Salvia, Matteo Bevilacqua, Riccardo Morganti, Salvatore Panduri, Giovanni Bagnoni, Marco Romanelli, Agata Janowska, Valentina Dini

{"title":"Correlation between skin cancer and therapy with anti-IL monoclonal antibodies in patients affected by moderate-to-severe psoriasis: an observational monocentric study.","authors":"Flavia Manzo Margiotta, Cristian Fidanzi, Simone Pardossi, Alessandra Michelucci, Giammarco Granieri, Giorgia Salvia, Matteo Bevilacqua, Riccardo Morganti, Salvatore Panduri, Giovanni Bagnoni, Marco Romanelli, Agata Janowska, Valentina Dini","doi":"10.1097/CEJ.0000000000000948","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000948","url":null,"abstract":"Our study aimed to investigate the correlation between skin cancer and anti-interleukin (IL) therapy in patients with moderate-to-severe psoriasis. This was an observational monocentric study in which we enrolled a total of 235 patients in which 127 patients were affected by moderate-to-severe psoriasis and treated with anti-IL monoclonal antibodies (mAbs) for at least 6 months, whereas 108 patients affected by mild psoriasis were treated with topical therapies. Afterward, we performed a dermatologic visit to all the subjects, collecting anamnestic information including risk factors for skin cancer. We examined the skin lesions on their entire body by polarized and nonpolarized dermoscopy. A total of 21 suspicious lesions in the first group and 17 in the second one were removed and histologically analyzed. Twelve (9.4%) cancerous or precancerous lesions were found in the first group: seven (5.5%) basal cell carcinoma (BCC) and five actinic keratosis. The mean time to cancer onset was identified as 22 months after the start of four therapy, with an SD of 18 months, suggesting an earlier onset with respect to the start of therapy in our population. On univariate analysis, age (P = 0.001) and age of psoriasis onset (0.009) were statistically significant. Nine of 17 were skin cancers in the second group. Our study provided real-life evidence of the percentage of patients with skin cancers during therapy with anti-IL mAbs, demonstrating a good safety profile of the investigated drugs.","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human papillomavirus vaccination coverage in Italy. 意大利的人类乳头瘤病毒疫苗接种覆盖率。

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-01 Epub Date: 2024-06-07 DOI: 10.1097/CEJ.0000000000000896

Giorgio Bogani, Giovanni Scambia, Francesco Raspagliesi, Giovanni Corso

引用次数: 0

Conditional survival of male breast cancer. 男性乳腺癌的条件生存率。

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-01 Epub Date: 2024-05-06 DOI: 10.1097/CEJ.0000000000000893

Yanshuai Fan, Chaoyue Ku, Ruizhe Wang, Binbin Wu, Man Cui, Juan Wang, Miao Deng, Li Liu, Zhiguang Ping

{"title":"Conditional survival of male breast cancer.","authors":"Yanshuai Fan, Chaoyue Ku, Ruizhe Wang, Binbin Wu, Man Cui, Juan Wang, Miao Deng, Li Liu, Zhiguang Ping","doi":"10.1097/CEJ.0000000000000893","DOIUrl":"10.1097/CEJ.0000000000000893","url":null,"abstract":"Background: The incidence of male breast cancer has been increasing in recent years; however, the long-term survival outcomes of diagnosed patients remain uncertain. This study was designed to evaluate the conditional survival of male breast cancer patients and to predict the future survival of patients through the conditional nomogram, to provide important suggestions for clinical decision-making.Methods: Retrospective data from the SEER database included 3600 male breast cancer patients, divided into training and validation groups (7 : 3 ratio). Overall survival rates were calculated using Kaplan-Meier analysis. Conditional survival analysis described survival at specific years. Time-dependent multivariate Cox analysis identified prognostic factors' impact. The conditional survival nomogram model predicted real-time survival rates.Results: Over time, the 5-year real-time survival rate of patients gradually improved, increasing from 70.5 to 74.8, 79.4, 85.8, and 92.9% (respectively, representing 5-year survival rates of 1-4 years after diagnosis). In addition, the improvement in conditional survival rate CS5 showed a nonlinear trend. After 5 years of diagnosis, age, tumor size, and tumor stage had a sustained impact on patient prognosis. Finally, a conditional survival nomogram was constructed to predict the 10-year survival rate in real time.Conclusion: Five years after diagnosis, the conditional survival rate of male patients with breast cancer has improved, but it is not nonlinear. In the first 5 years after diagnosis, patients with older age, larger tumor size, poorer tumor stage, and distant metastasis should be actively followed up and treated to improve their long-term survival.","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"66-75"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncoplastic breast surgery: where are we now. 乳房肿瘤整形手术：我们现在在哪里？

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1097/CEJ.0000000000000923

Francesca De Lorenzi, Mario Alessandri-Bonetti

引用次数: 0

Physical activity and exercise health benefits: cancer prevention, interception, and survival. 体育活动和锻炼对健康的益处：癌症预防、拦截和生存。

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-01 Epub Date: 2024-06-26 DOI: 10.1097/CEJ.0000000000000898

Adriana Albini, Carlo La Vecchia, Francesca Magnoni, Ornella Garrone, Danilo Morelli, Jaak Ph Janssens, Alain Maskens, Gad Rennert, Viviana Galimberti, Giovanni Corso

{"title":"Physical activity and exercise health benefits: cancer prevention, interception, and survival.","authors":"Adriana Albini, Carlo La Vecchia, Francesca Magnoni, Ornella Garrone, Danilo Morelli, Jaak Ph Janssens, Alain Maskens, Gad Rennert, Viviana Galimberti, Giovanni Corso","doi":"10.1097/CEJ.0000000000000898","DOIUrl":"10.1097/CEJ.0000000000000898","url":null,"abstract":"Physical activity (PA) has an established role in the promotion of health and fitness and the prevention of disease. Expected overall benefits include reduction of all-cause morbidity and death, weight control, improved quality of life, improved bone health and decreased falls of elderly subjects, , deeper cognition, and reduced risk of depression, anxiety, and sleeplessness. Currently, PA is a mainstay in the management of cardiovascular diseases, metabolic syndrome, diabetes, and bone health. Recently, the perception of its role in primary and secondary prevention, interception, and treatment of cancer, however, is also gaining importance. Regular walking, the simplest type of PA, is associated with reduced all-cause and cardiovascular disease mortality, and a role in cancer prevention is of increasing interest. Furthermore, PA improves the quality of life of cancer patients, attenuating side effects of chemotherapy, decreasing sarcopenia, increasing fitness, and inhibiting the recurrence and progression of some cancer types. It promotes emotional and psychological benefits in patients, inducing positive changes. While mechanisms, effective levels and useful amount of PA practice are well established in cardiology, they are yet to be fully determined in oncology. Nevertheless, PA is recommended to reduce cancer risk in the general population, and it has been introduced in programs for the prevention of second cancers. In perspective, it will help as integrative therapy in cancer patients and for cancer survivors. The number of beneficial effects in the cancer continuum is highlighted in this review.","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"24-39"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular death risk in patients with solid tumors: a population-based study in the United States. 实体瘤患者的心血管死亡风险：一项基于美国人口的研究。

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-01 Epub Date: 2024-08-26 DOI: 10.1097/CEJ.0000000000000921

Shuaijie Gao, Hao Zhu, Xinyu Chang, Xiting Cao, Zhenwei Wang, Xiaoxuan Chu, Lu Zhang, Xinhua Wang, Jie Lu

{"title":"Cardiovascular death risk in patients with solid tumors: a population-based study in the United States.","authors":"Shuaijie Gao, Hao Zhu, Xinyu Chang, Xiting Cao, Zhenwei Wang, Xiaoxuan Chu, Lu Zhang, Xinhua Wang, Jie Lu","doi":"10.1097/CEJ.0000000000000921","DOIUrl":"10.1097/CEJ.0000000000000921","url":null,"abstract":"Background: Previous studies have focused on the risk of cardiovascular disease (CVD)-specific death in hematological cancers and in some single anatomical tumor sites, there remains a paucity of data on systematic analyses in solid tumors.Objective: The objective of this study is to evaluate the distribution, risk, and trends of CVD-specific death in patients with solid tumors.Methods: A total of 2 679 293 patients with solid tumors diagnosed between 1975 and 2019 were screened from the Surveillance, Epidemiology and End Results (SEER) program across 15 anatomical sites. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were used to describe the intensity of CVD-specific death, competing risk regression models were used to assess the risk of CVD-specific death, and restricted cubic spline analyses were employed to investigate the potential linear or nonlinear relationship between age and CVD death.Results: CVD-specific death in patients with solid tumors accounted for 48.95% of non-cancer deaths. Compared with the general population, patients with solid tumors had higher SMR and AER of CVD death (SMR: 1.15; AER: 21.12), heart disease-related death (SMR: 1.13; AER: 13.96), and cerebrovascular disease-related death (SMR: 1.20; AER: 4.85). Additionally, the SMR exhibited a decreasing trend with increasing time to diagnosis. Furthermore, a nonlinear relationship was observed between age and CVD-specific death in patients with solid tumors of different systems.Conclusion: CVD-specific death accounted for a large proportion of the cause of non-cancer deaths. Patients with solid tumors exhibit an elevated risk of CVD-specific death. Screening for CVD death and optimizing risk management in patients with solid tumors throughout anticancer treatment may be beneficial in preventing CVD death.","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"11-23"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between birth weight and risk of nonneurological childhood cancers: a systematic review and meta-analysis. 出生体重与儿童罹患非神经系统癌症风险之间的关系：系统回顾与荟萃分析。

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-01 Epub Date: 2024-05-20 DOI: 10.1097/CEJ.0000000000000894

Roya Rashti, Faezeh Ghasemi, Jalal Poorolajal

{"title":"Association between birth weight and risk of nonneurological childhood cancers: a systematic review and meta-analysis.","authors":"Roya Rashti, Faezeh Ghasemi, Jalal Poorolajal","doi":"10.1097/CEJ.0000000000000894","DOIUrl":"10.1097/CEJ.0000000000000894","url":null,"abstract":"Objectives: This systematic review aims to synthesize the available literature to determine the association between birthweight and the risk of nonneurological childhood cancers.Methods: We conducted a systematic search of PubMed, Web of Science, and Scopus databases up to May 2023 to identify observational studies. Heterogeneity between studies was evaluated using the I2 statistics. Publication bias was assessed using Begg and Egger tests. We calculated the odds ratio (OR) or risk ratio (RR) with a 95% confidence interval (CI) using a random-effects model.Results: Of 11 034 studies retrieved from the search, 56 studies (including 10 568 091 participants) were eligible. The ORs (95% CI) of low (<2500 g) versus normal birthweight (2500-4000 g) and childhood cancers were as follows: leukemia, 0.92 (0.77-1.11); acute lymphoblastic leukemia, 0.82 (0.72-0.94); acute myeloid leukemia, 0.98 (0.77-1.24); lymphoma, 0.99 (0.47-2.10); Hodgkin, 0.79 (0.61-1.03); non-Hodgkin, 0.85 (0.60-1.20); neuroblastoma, 1.34 (1.14-1.58); retinoblastoma, 0.95 (0.68-1.32); rhabdomyosarcoma, 0.86 (0.61-1.20); embryonal, 0.97 (0.66-1.43); alveolar, 1.92 (0.43-8.51); and Wilms tumor, 1.01 (0.83-1.24). The ORs (95% CI) of high (>4000 g) versus normal birthweight and childhood cancers were as follows: leukemia, 1.30 (1.18-1.42); acute lymphoblastic leukemia, 1.27 (1.16-1.39); acute myeloid leukemia, 1.13 (0.98-1.30); lymphoma, 1.69 (0.72-3.94); Hodgkin, 1.22 (1.02-1.46); non-Hodgkin, 1.22 (0.80-1.86); neuroblastoma, 1.20 (1.02-1.41); retinoblastoma, 1.17 (0.93-1.48); rhabdomyosarcoma, 1.07 (0.90-1.27); embryonal, 1.22 (1.00-1.49); alveolar, 1.02 (0.46-2.27); and Wilms tumor, 1.49 (1.34-1.67).Conclusion: This meta-analysis identified high birth weight as a potential risk factor for some childhood cancers, while low birth weight might be protective against a few.","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"40-52"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring breast cancer screening fear through a psychosocial lens. 从社会心理角度探讨乳腺癌筛查恐惧。

IF 2.1 4区医学

European Journal of Cancer Prevention Pub Date : 2025-01-01 Epub Date: 2024-05-15 DOI: 10.1097/CEJ.0000000000000895

Vikas Burugu, Mary Salvatore

{"title":"Exploring breast cancer screening fear through a psychosocial lens.","authors":"Vikas Burugu, Mary Salvatore","doi":"10.1097/CEJ.0000000000000895","DOIUrl":"10.1097/CEJ.0000000000000895","url":null,"abstract":"Breast cancer screening is crucial for early detection and treatment. Yet, underutilization persists due to various psychosocial factors. This manuscript delves into the multifaceted fears that hinder screening adherence. The literature provides a framework categorizing breast cancer screening fears into generalized cancer fear, fear of screening components, and fear of screening outcomes. In this review, we explore fear of screening components (concerns regarding radiation, discomfort, and pain) and fear of screening outcomes (disability and mortality apprehension, treatment fears, obligation anxiety, and financial concerns) as undesirable, and potentially addressable, aspects of breast cancer screening fear. False-positive results exacerbate these anxieties, prolonging distress and impacting patients' lives beyond the screening process. Addressing these concerns requires reframing current screening approaches to prioritize patient comfort, cultural sensitivity, and accessibility. To address current psychosocial challenges in breast cancer screening, this manuscript advocates for modifying breast cancer screening methods to improve adherence and patient well-being.","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"76-80"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0